ADNI
Cross-source consensus on ADNI from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Preparation
Where it comes from
Highlighted claims
- Real-world evaluation used baseline ADNI ADNIMERGE visits from CN, EMCI, LMCI, and AD participants. — TEMPO: Transformers for Temporal Disease Progression from Cross-Sectional Data
- The ADNI analysis included 726 participants after excluding those missing any selected biomarker. — TEMPO: Transformers for Temporal Disease Progression from Cross-Sectional Data
- Predicted ADNI stages increased monotonically from CN to AD diagnosis groups. — TEMPO: Transformers for Temporal Disease Progression from Cross-Sectional Data
- TEMPO's ADNI consensus sequence began with entorhinal, middle temporal, and fusiform biomarkers. — TEMPO: Transformers for Temporal Disease Progression from Cross-Sectional Data